Potential Impact of Emerging Therapies on Patients Living with ITP

EP: 1.Understanding Immune Thrombocytopenia: Pathophysiology, Classification, and Differentiation

EP: 2.Diagnostic and Patient Education Strategies in ITP

EP: 3.Managing Bleeding Risk in Patients with ITP

EP: 4.Living with ITP: Impact of Fatigue and Other Symptoms on Patients’ Quality of Life

EP: 5.Tailoring Care in ITP Through a Health Equity Lens

EP: 6.Looking Ahead in ITP: Addressing Unmet Needs and Embracing Innovation

EP: 7.Key Clinical Signs and Symptoms Used in Diagnosis of Immune Thrombocytopenia

EP: 8.Clinical Decision-Making in ITP: Timing Treatment Initiation and Therapy Goals

EP: 9.Current Treatment Algorithm for Management of Immune Thrombocytopenia

EP: 10.Addressing the Limitations of Current ITP Therapies

EP: 11.Risks versus Benefits: ITP Treatment Side Effects and the Influence on Patients’ Quality of Life

EP: 12.Defining Treatment Success, Failure, and When to Reassess Patients’ Management of ITP

EP: 13.Navigating Refractory ITP: Clinical Insights and Treatment Strategies

Now Viewing

EP: 14.Potential Impact of Emerging Therapies on Patients Living with ITP

The field of ITP treatment is evolving rapidly with several exciting new agents under investigation. One promising class includes Bruton’s tyrosine kinase inhibitors, which have shown potential in recent studies. Additionally, a novel neonatal Fc receptor antagonist is emerging as a new therapeutic option, alongside other treatments like anti-CD38 antibodies that are also being explored for their role in ITP.

An interesting development involves the use of CAR T-cell therapy, which targets the B cells that produce the antibodies responsible for autoimmune platelet destruction. Some patients with lymphoma and concurrent ITP have received CAR T therapy, resulting in sustained platelet counts over an extended period. This approach represents a novel and intense treatment strategy compared to conventional therapies.

Overall, the growing array of treatment options—ranging from intravenous to oral agents, and even cell-based therapies like CAR T—offers new hope for optimizing outcomes in ITP. Combining different treatments may provide the best results, and these innovative therapies continue to expand the possibilities for managing this challenging condition.